Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Kineta (KA) has shared an update.
Kineta, Inc. has shared exciting news in their latest press release about the progress of their VISTA-101 Phase 1/2 clinical trial. Their innovative immunotherapy treatment, KVA12123, is currently being tested on patients with advanced solid tumors. This update marks a significant milestone for the company and holds potential implications for the future of cancer treatment.
See more data about KA stock on TipRanks’ Stock Analysis page.